Home

Insights

Natco Pharma Ltd P/E Ratio

Natco Pharma Ltd P/E Ratio

download
stocks purchased

₹ 0.7 Cr

Volume transacted

stocks purchased

7.3 K

stocks traded

Image

Natco Pharma Ltd

NSE: NATCOPHARM

PE

14

Last updated : 19 May 01:32 AM

Key Highlights

    The P/E Ratio of Natco Pharma Ltd is 14 as of 19 May 01:32 AM .a1#The P/E Ratio of Natco Pharma Ltd changed from 16.2 on March 2019 to 14.4 on March 2023 . This represents a CAGR of -2.33% over 5 years. a1#The Latest Trading Price of Natco Pharma Ltd is ₹ 999.35 as of 18 May 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 27.2. The PE Ratio of Finance industry is 13.6. The PE Ratio of IT - Software industry is 27.9. The PE Ratio of Pharmaceuticals industry is 27.7. The PE Ratio of Retail industry is 94.8. The PE Ratio of Textiles industry is 21.1. In 2023a1#The Market Cap of Natco Pharma Ltd changed from ₹ 10515 crore on March 2019 to ₹ 10289 crore on March 2023 . This represents a CAGR of -0.43% over 5 years. a1#The Revenue of Natco Pharma Ltd changed from ₹ 918.9 crore to ₹ 795.6 crore over 7 quarters. This represents a CAGR of -7.90% a1#The EBITDA of Natco Pharma Ltd changed from ₹ 429.6 crore to ₹ 305.1 crore over 7 quarters. This represents a CAGR of -17.76% a1#The Net Profit of Natco Pharma Ltd changed from ₹ 320.4 crore to ₹ 212.7 crore over 7 quarters. This represents a CAGR of -20.87% a1#The Dividend Payout of Natco Pharma Ltd changed from 17.1 % on March 2019 to 15.75 % on March 2023 . This represents a CAGR of -1.63% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1916.2
Mar '2020
Mar '2134.2
Mar '2281.3
Mar '2314.4

Fundamental Metrics

Market Cap

17,899 Cr

EPS

71.3

P/E Ratio (TTM) *

14.0

P/B Ratio (TTM) *

3.4

Day’s High

1006.95

Day’s Low

995.0

DTE *

0.0

ROE *

21.3

52 Week High

1107.85

52 Week Low

609.55

ROCE *

24.5

* All values are consolidated

* All values are consolidated

Image

Natco Pharma Ltd

NSE: NATCOPHARM

PRICE

999.35

4.25(0.43%)

stock direction

Last updated : 18 May 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Natco Pharma Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

2

T

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

17,899

Asset Value

2,891

5.2 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

1,277 Cr

14.0 X

PE Ratio

Market Cap

₹17899Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

1,277 Cr

14.0 X

PE Ratio

Market Cap

₹17899Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Natco Pharma Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Natco Pharma Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Natco Pharma Ltd's Share Price stands at 999.35. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-05-18T00:00:00 is 71.34. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 999.35/ 71.34= 14.01.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Natco Pharma Ltd's stock is trading at approximately 14.01 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Natco Pharma Ltd’s PE Ratio (BSE: NATCOPHARM)

    The Price-to-Earnings (PE) ratio, used to assess Natco Pharma Ltd's stock (BSE: NATCOPHARM), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '1910515
Mar '209215
Mar '2115046
Mar '2213822
Mar '2310290

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22919
Sep '22453
Dec '22513
Mar '22927
Jun '231160
Sep '231061
Dec '23796

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '22430
Sep '22116
Dec '22127
Mar '22368
Jun '23548
Sep '23487
Dec '23305

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '22320
Sep '2257
Dec '2262
Mar '22276
Jun '23420
Sep '23369
Dec '23213

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1917
Mar '2026
Mar '2131
Mar '2259
Mar '2316

* All values are a in %

About Natco Pharma Ltd

About Natco Pharma Ltd

    Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh. In 2003, Natco Pharma launched its Oncology division with introduction of flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia. In 2014, Natco Pharma established a subsidiary Natco Pharma Australia Pty Ltd for sales and distribution in Australia. On 9 March 2015, Natco Pharma announced that it has launched the first generic version of sofosbuvir in Nepal. The Committee of Directors of Natco Pharma at its meeting held on 14 December 2017 approved allocation of 1 crore Equity Shares at the issue price of Rs 915 per Equity (including a premium of Rs. It launched the Bendamustine Injection and Anastrozole tablets by the subsidiary named, Natco Lifesciences Philippines Inc. It launched the first generic of Oseltamivir in Brazil.

Natco Pharma Ltd News Hub

News

Natco Pharma Ltd rises for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 990...

Read more

14 May 2024 13:05

News

Natco Pharma to hold board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 27 May 2024 P...

Read more

09 May 2024 16:50

News

Natco Pharma update on legal complaint filed in US

NATCO Pharma announced that Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH (t...

Read more

18 Apr 2024 09:30

News

Natco Pharma receives warning letter from USFDA for its Kothur unit

Natco Pharma has received a warning letter dated 08 April 2024 from the United States Food...

Read more

09 Apr 2024 10:35

News

Natco Pharma Ltd leads gainers in 'A' group

Axis Bank Ltd, Linde India Ltd, Pidilite Industries Ltd and Kotak Mahindra Bank Ltd are am...

Read more

06 Mar 2024 12:00

News

Natco Pharma Ltd soars 3.1%, gains for fifth straight session

Natco Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1058...

Read more

19 Feb 2024 13:00

Product Composition by Percentage (Revenue)

FAQs for PE of Natco Pharma Ltd

What is Natco Pharma Ltd current share price?

The current market price of Natco Pharma Ltd as of May 19, 2024 is ₹999.35.

Is Natco Pharma Ltd a good investment?

As per BlinkX Score Natco Pharma Ltd scores 18 in Revenue, 18 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Natco Pharma Ltd's total net assets?

According to Natco Pharma Ltd's most recent financial filings, the company's net assets total ₹2890.7 Cr.

Is Natco Pharma Ltd making a profit or loss?

Natco Pharma Ltd's net Profit as of May 19, 2024 is close to ₹1,277 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199